KRAS and cancer: Combining with other keywords active at that time, the preliminary research concentrated on clinical trials and efficacy using drugs like gefitinib, cetuximab plus irinotecan, and erlotinib that target the KRAS upstream gene EGFR in cancer patients with KRAS mutations (35, 36).